www.chemicalsknowledgehub.com
Horizon says that its insight into the challenges faced by these organisations enables it to focus its efforts on the development of innovative solutions that not only differentiate its offering, but that also fuel development of the next wave of precision medicines
proteins to support researchers from early drug development through to commercial manufacturing.
The two companies say
that by entering into the agreement, they aim to empower organisations of all sizes, from large pharmaceutical companies to clinical stage biotechs and early-stage startups, to drive efficiencies in biotherapeutic manufacturing and that Rentschler Biopharma’s integrated platform process, together with Horizon’s cell line, will provide innovative and tailored solutions to translate complex medical research into new biopharmaceuticals, elevating the standard of protein expression and allowing clients to access a robust and flexible approach for designer protein therapeutics from concept to market.
Rentschler Biopharma SE and Horizon signed a commercial licence agreement under which Horizon’s cGMP-compliant CHOSOURCE platform will be used in combination with Rentschler Biopharma’s novel in-house process for cell line development for difficult-to- express proteins. Horizon’s gene-edited glutamine synthetase (GS) knockout CHO K1 cGMP-compliant cell line will complement Rentschler Biopharma’s existing service offering, providing a royalty-free, state-of-the-art alternative for the production of highly complex
Immunotherapy development
Horizon had earlier announced that the CHOSOURCE platform had played a key role in generating a stable cell line for the development of an immunotherapy for autoimmune diseases with pharmaceutical-grade, stable CHO cells delivering high yields of monoclonal antibody for LAG-3 immunotherapy, enabling Immutep and Batavia Biosciences to reach an important milestone in the preclinical development of the compound. The company’s
Life Sciences Focus: Drug Discovery
gene-edited GS knockout CHO K1 cell line expression system, offered by Batavia Biosciences as part of its STEP-mAb service, was used to generate a high yielding cell line for Immutep’s IMP761 product candidate, an agonist antibody targeting the immune checkpoint lymphocyte activation gene LAG-3 which controls the signaling between specific immune cells, T cells and antigen-presenting cells responsible for the adaptive immune response, making it a promising focus for novel cancer therapies or for the treatment of autoimmune conditions such as inflammatory bowel diseases, rheumatoid arthritis, and multiple sclerosis.
In yet another CHOSOURCE
platform development, Horizon announced in April this year that it was offering special licensing terms to facilitate rapid access to the CHOSOURCE for the development of COVID- 19-related therapeutics and diagnostics. Horizon is already a key supplier for COVID-19- related research as a provider of tools and services to academia and industry in their efforts in the pandemic.
Arrayed CRISPR knockout screening service Also in April, Horizon announced the addition to its cell-based screening services of an arrayed CRISPR knockout screening service for primary human
B cells, cells that are freshly isolated from donors and known to be difficult to study in the lab. One advantage of working with these cells, however, is that it brings scientists one step closer to healthy or diseased micro-environments, enabling them to better understand disease etiology and therapeutic mechanisms and thereby advance drug discovery and development programmes. Horizon has already applied its gene editing and cell culture expertise to maintain the viability of primary human T cells to enable functional genomic screens and has been delivering data-rich information to customers working in drug discovery and development. Horizon says the new B cell screening service, the first of its kind in the market, will enable researchers to identify genes that affect the function of B cells and examine how this impacts other immune cell types, particularly in infectious diseases, cancer, and auto-immune disorders, such as COVID-19, Burkitt’s lymphoma and multiple sclerosis, respectively.
Further information Horizon Discovery plc Cambridge, UK
Ph: +44-1223-976160 E: technical@
horizondiscovery.com W: www.horizondiscovery. com
Get recognized for your achievements
ENTRIES NOW OPEN Summer 2020 17
Ethical Innovation Awards 2021
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60
